title: The use of protease inhibitors in experimental allergic neuritis.
abstract: In experimental allergic neuritis (EAN) break-down of myelin is attributed to macrophages, which among other factors contain and secrete proteases. In vitro studies have shown that cathepsin D, an acidic aspartyl endopeptidase, and plasmin can degrade myelin proteins. In order to elucidate a potential therapeutic effect of protease inhibitors we treated Lewis rats, immunized with bovine peripheral nervous system myelin, with epsilon-amino-caproic acid (EACA) or pepstatin. EACA or pepstatin was administered twice daily by intraperitoneal injection beginning on day 6 postimmunization or from the onset of disease (on day 12) through day 24. Compared to saline-treated controls, animals treated with either of the inhibitors showed delayed development of clinical signs and electrophysiological abnormalities. Maximal severity and the further course of disease, however, were not different in control and treated groups. Immunohistological evaluation of sciatic nerve specimens on day 24 postimmunization showed equal numbers of cells positive for ED1 (macrophages) and cathepsin D in all animal groups. There was also no difference in the spontaneous proteolytic activity of the sciatic nerve homogenates at pH 2.8, 5.0, and 7.4. Incubation of the homogenates with pepstatin, however, significantly reduced proteolytic activity at pH 2.8 and 5.0, while EACA had no effect at any pH tested. These results imply that treatment to limit the infiltration of cathepsin D-positive cells or to reduce the induction or activity of cathepsin D may provide a therapeutic avenue for treating inflammatory demyelination of the peripheral nervous system.
authors.affiliation: Department of Neurology, Klinikum Schnarrenberg, University of Tübingen, F.R.G.
authors.forename: M
authors.initials: M
authors.lastname: Schabet
authors.forename: J N
authors.initials: JN
authors.lastname: Whitaker
authors.forename: K
authors.initials: K
authors.lastname: Schott
authors.forename: A
authors.initials: A
authors.lastname: Stevens
authors.forename: A
authors.initials: A
authors.lastname: Zürn
authors.forename: R
authors.initials: R
authors.lastname: Bühler
authors.forename: H
authors.initials: H
authors.lastname: Wiethölter
mesh_terms: D015119:Aminocaproic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D002402:Cathepsin D / Q000032:analysis; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000209:etiology; D005260:Female; D005341:Fibrinolysin / Q000502:physiology; D009444:Neuritis, Autoimmune, Experimental / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D010436:Pepstatins / Q000494:pharmacology / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use*; D051381:Rats; D011917:Rats, Inbred Lew; D012584:Sciatic Nerve / Q000201:enzymology
chemical_list: D010436:Pepstatins; D011480:Protease Inhibitors; C014195:Streptomyces pepsin inhibitor; D005341:Fibrinolysin; D002402:Cathepsin D; D015119:Aminocaproic Acid; C031375:pepstatin